Chilblain lupus erythematosus--a review of literature
- PMID: 18543054
- DOI: 10.1007/s10067-008-0942-9
Chilblain lupus erythematosus--a review of literature
Erratum in
- Clin Rheumatol. 2008 Oct;27(10):1341. Lee-Kirsch, Min Ae [added]
Abstract
Chilblain lupus erythematosus (CHLE) is a rare, chronic form of cutaneous lupus erythematosus. Sporadic cases and two families with autosomal dominant-inherited CHLE have been reported. In familial CHLE, two missense mutations in TREX1 encoding the 3'-5' repair exonuclease 1 were described in affected individuals. The pathogenesis of sporadic CHLE remains unknown. Up to 20% of patients develop systemic lupus erythematosus (SLE). An association with anorexia is discussed. In many cases, there is good response to symptomatic therapy. SLE therapeutics have good effects on SLE-typical symptoms but not on chilblains themselves. This article reviews the clinical presentation, pathogenesis, diagnosis and treatment of CHLE. As an index patient with unique features, we report a 13-year-old boy developing CHLE after anorexia nervosa. Sequencing of TREX1 was normal. With psychotherapeutic support for anorexia and after antibiotic therapy, topical steroids, physical warming and calcium channel blockers, the patient experienced significant relief. Improvement of phalangeal perfusion was demonstrated by angio-MRI.
Similar articles
-
Assessment of Clinical Response to Janus Kinase Inhibition in Patients With Familial Chilblain Lupus and TREX1 Mutation.JAMA Dermatol. 2019 Mar 1;155(3):342-346. doi: 10.1001/jamadermatol.2018.5077. JAMA Dermatol. 2019. PMID: 30673078 Free PMC article.
-
Familial chilblain lupus due to a novel mutation in the exonuclease III domain of 3' repair exonuclease 1 (TREX1).JAMA Dermatol. 2015 Apr;151(4):426-31. doi: 10.1001/jamadermatol.2014.3438. JAMA Dermatol. 2015. PMID: 25517357
-
Systemic involvement in TREX1-associated familial chilblain lupus.J Am Acad Dermatol. 2013 Oct;69(4):e179-81. doi: 10.1016/j.jaad.2013.04.020. J Am Acad Dermatol. 2013. PMID: 24034389 No abstract available.
-
Chilblains in immune-mediated inflammatory diseases: a review.Rheumatology (Oxford). 2022 Nov 28;61(12):4631-4642. doi: 10.1093/rheumatology/keac231. Rheumatology (Oxford). 2022. PMID: 35412601 Free PMC article. Review.
-
Familial Chilblain Lupus - What Can We Learn from Type I Interferonopathies?Curr Rheumatol Rep. 2017 Aug 26;19(10):61. doi: 10.1007/s11926-017-0689-x. Curr Rheumatol Rep. 2017. PMID: 28844088 Review.
Cited by
-
The Impact of COVID-19 Pandemic on Dermatological Conditions: A Novel, Comprehensive Review.Dermatopathology (Basel). 2022 Jun 29;9(3):212-243. doi: 10.3390/dermatopathology9030027. Dermatopathology (Basel). 2022. PMID: 35892480 Free PMC article. Review.
-
Chilblain lupus erythematosus.BMJ Case Rep. 2013 Nov 27;2013:bcr2013201165. doi: 10.1136/bcr-2013-201165. BMJ Case Rep. 2013. PMID: 24285807 Free PMC article.
-
Ocular Complications in Cutaneous Lupus Erythematosus: A Systematic Review with a Meta-Analysis of Reported Cases.J Ophthalmol. 2015;2015:254260. doi: 10.1155/2015/254260. Epub 2015 Jun 11. J Ophthalmol. 2015. PMID: 26171240 Free PMC article. Review.
-
Clinical aspects of cutaneous lupus erythematosus.Front Med (Lausanne). 2023 Jan 9;9:984229. doi: 10.3389/fmed.2022.984229. eCollection 2022. Front Med (Lausanne). 2023. PMID: 36698816 Free PMC article. Review.
-
Cutaneous Manifestations of COVID-19: Case Report and Discussion.HCA Healthc J Med. 2020 Nov 28;1:391-394. doi: 10.36518/2689-0216.1130. eCollection 2020. HCA Healthc J Med. 2020. PMID: 37426856 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials